PI3K-gamma Inhibitors
1 drugsAbout PI3K-gamma
PI3K-gamma is a lipid kinase enzyme involved in cell signaling pathways that regulate cell growth, proliferation, survival, and migration. As a specific isoform of the PI3K family, it has a unique expression pattern making it an attractive therapeutic target.
PI3K-gamma is a drug target in oncology, though no genetic evidence currently links it to specific diseases. The existing drug approval highlights its relevance as a target, and inhibitors hold promise for advancing cancer treatment.
There is one FDA-approved drug, COPIKTRA (marketed by SECURA), that targets PI3K-gamma as a small molecule. It has two indications in oncology and was first approved in 2018.
Top PI3K-gamma Drugs
SECURA is the only company with an approved drug targeting PI3K-gamma.
Low competition represents an opportunity, but also a risk due to limited market validation.
PI3K-gamma Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PI3K-gamma, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation.
PI3K-gamma Clinical Trials 40 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PI3K-gamma. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 6 | 8 | 7 | 43% |
| Phase 2 | 15 | 7 | 4 | 4 | 64% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved PI3K-gamma drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PI3K-gamma. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PI3K-gamma Drug Approval Timeline (2018 - 2018)
COPIKTRA was first approved in 2018 and remains the only approved drug.
The lack of recent approvals suggests potential saturation or challenges in targeting PI3K-gamma.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PI3K-gamma. A trial counts if an approved drug acting on PI3K-gamma is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.